Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616694 | 0.90 | PIK3CD (0.38) | TYRPTGS1PTGS2CYP19A1NPC1 | |
| SCHEMBL29871375 | 0.80 | ALDH1A1 (0.43) | TYRHSP90AA1RAB9ACYP3A4CHRNB2 | |
| SCHEMBL3162433 | 0.80 | ALDH1A1 (0.43) | TYRHSP90AA1RAB9ACYP3A4CHRNB2 | |
| SCHEMBL29429338 | 0.79 | PIK3CD (0.42) | TYRPTGS1PTGS2CYP19A1NPC1 | |
| SCHEMBL614735 | 0.79 | PIK3CD (0.42) | TYRPTGS1PTGS2CYP19A1NPC1 | |
| SCHEMBL70722 | 0.78 | ALDH1A1 (0.46) | TYRHSP90AA1CHRNB2CHRNA4 | |
| SCHEMBL5935862 | 0.78 | ALDH1A1 (0.46) | TYRHSP90AA1CHRNB2CHRNA4 | |
| SCHEMBL19892266 | 0.78 | ALDH1A1 (0.46) | TYRHSP90AA1CHRNB2CHRNA4 | |
| Water SCHEMBL4974800 | 0.78 | ALDH1A1 (0.42) | TYRHSP90AA1RAB9ACYP3A4CHRNB2 | |
| SCHEMBL31545836 | 0.78 | ALDH1A1 (0.46) | TYRHSP90AA1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016102398-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102399-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102402-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| WO-2016102400-A1 | COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| EP-2529735-B1 | COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY | GALDERMA RES & DEV (FR) | 2014-06-25 | — | — | EP | claimed |
| US-8372879-B2 | 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-02-12 | — | — | US | claimed |
| EP-2529735-A1 | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | Galderma Research & Development (FR) | 2012-12-05 | — | — | EP | claimed |
| EP-2373310-B1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-10-10 | — | — | EP | claimed |
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-16 | — | — | US | claimed |
| EP-2373310-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | Galderma Research & Development (FR) | 2011-10-12 | — | — | EP | claimed |
| WO-2010063773-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | claimed |
| US-9745281-B2 | Method for the synthesis of 4-(heterocycloalkyl)-benzene-1,3,-diol compounds | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-29 | — | — | US | disclosed |
| EP-2956449-B1 | PROCESS FOR THE PREPARATION OF 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUNDS | GALDERMA RES & DEV (FR) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016102402-A1 | AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102400-A1 | COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT | L'OREAL (FR) | 2016-06-30 | — | — | WO | disclosed |
| EP-2529735-A1 | Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics | Galderma Research & Development (FR) | 2012-12-05 | — | — | EP | disclosed |
| EP-2373310-B1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2373310-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | Galderma Research & Development (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063773-A1 | NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041213-A1 | 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS | TYR, DDT, PAH | PDE3B 681/4885PDE3A 596/4885TYR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.